Project description:Strain Parabacteroides merdae TSDC10.2-1.1 (species Parabacteroides merdae) was isolated from the fecal microbiota of a USA female at time point zero (bacterial isolates were sequenced from this donor on day 0 and 42). The species name was assigned by genome clustering.
Project description:Strain Parabacteroides merdae TSDC10.2-1.2 (species Parabacteroides merdae) was isolated from the fecal microbiota of a USA female at time point zero (bacterial isolates were sequenced from this donor on day 0 and 42). The species name was assigned by genome clustering.
Project description:Strain Parabacteroides merdae TSDC10.1-1.1 (species Parabacteroides merdae) was isolated from the fecal microbiota of a USA female at time point zero (bacterial isolates were sequenced from this donor on day 0 and 42). The species name was assigned by genome clustering.
Project description:Strain Parabacteroides merdae TSDC19.1-1.1 (species Parabacteroides merdae) was isolated from the fecal microbiota of a USA female at time point zero (bacterial isolates were sequenced from this donor on day 0 and 47). The species name was assigned by genome clustering.
Project description:Strain Parabacteroides merdae TSDC19.1-1.2 (species Parabacteroides merdae) was isolated from the fecal microbiota of a USA female at time point zero (bacterial isolates were sequenced from this donor on day 0 and 47). The species name was assigned by genome clustering.
Project description:The objective of this project was to identify changes in protein expression in R. intestinalis and P. merdae as a response to the treatment with the antidepressant duloxetine, the sweetener isosteviol and a combination of both. 18 samples before and after treatment were collected for each of the two species under anaerobic conditions. The species were inoculated from frozen stock cultures, three replicates each, into mGAM medium and passaged twice over night. Passage two was inoculated into 60 ml (120 ml for R. intestinalis) medium and pre-exposure0 samples were collected directly hereafter (three per species, one sample per replicate). The second pre-exposure samples were collected upon reaching exponential growth, directly prior to splitting each replicate into four equal sized batches, one per condition: Mock (DMSO, 0.2 %), 50 µM duloxetine, 50 µM isosteviol and a combination of both, 50 µM each. This results in 12 treatment samples, three per treatment, whereas each of the replicates can be traced back to one preculture. Bacteria were grown in the presence of the compounds at 37˚C for four hours, before final sample collection. Pre-exposure samples were collected as controls to monitor changes in protein expression in different growth stages.
